SMMT heads into the final days of August with a clear divergence between two analyst camps — and a $50 million insider vote of confidence from the top of the company still sitting in recent memory.
The most notable event this week was Bernstein's upgrade on August 25. The firm lifted SMMT from Underperform to Market Perform, raising its target from $9.80 to $11.90 — a meaningful reversal for a house that initiated with a bearish stance just three months ago at $7.70. That move stands in contrast to names like Stifel and Guggenheim, which maintained Buy ratings after the Q2 print but trimmed targets sharply — from $45 to $38 and from $40 to $38 respectively. Leerink Partners also upgraded to Market Perform from Underperform in mid-August, lifting its target to $13. The pattern is a Street gradually pulling off its most bearish stances, but not yet turning constructive — bulls holding reduced targets, bears stepping back rather than flipping. HC Wainwright sits at Neutral with no published target.
The mean analyst price target of $21.05 sits well above the current price of $13.36. Given the wide spread of views — targets ranging from $11.90 to $38 — and the recent cluster of downgrades and upgrades, that mean should be interpreted with caution rather than treated as a single directional signal. The stock is up 4.2% on the week, recovering modestly after a 2.2% slide over the prior month. Q3 results are due October 20.
Insider conviction offers the starkest data point in the whole picture. In the 90 days to mid-June, insiders net bought roughly 3.96 million shares worth $52 million. Chairman and co-CEO Robert Duggan led with a $50 million purchase of 3.81 million shares at $13.12 on June 12 — almost exactly the current price level. President and CEO Mahkam Zanganeh added 100,000 shares at $14.60 on the same date, and CFO Manmeet Soni made two separate purchases totalling 50,000 shares. That is a coordinated cluster across three senior executives, with Duggan now holding nearly 72% of shares outstanding. The buying came at prices close to where the stock trades today, which makes the cluster hard to dismiss.
Short positioning tells a less alarming story than the insider activity might imply there is to worry about. Short interest runs at 4.8% of the free float — meaningful but not extreme — and has drifted modestly lower from mid-July highs above 38 million shares to around 37 million. Borrow availability is running at roughly 144%, well inside the 52-week range that has touched near zero at its tightest. Cost to borrow is just 0.64%, up around 18% on the week but still firmly in low-cost territory. The ORTEX short score sits at 73.8, placing SMMT in the bottom 9th percentile on short score rank — meaning it screens as a moderately elevated short candidate relative to its universe — but the lending market itself shows no signs of a squeeze setup. Options traders are similarly calm: the put/call ratio of 0.55 is barely above its 20-day average of 0.54, with a z-score close to zero, a long way from the defensive extremes of 1.21 seen earlier in the year.
The bull case rests on ivonescimab's clinical trajectory and the ridinilazole antibiotic programme, with forward EPS estimates showing sharp year-on-year improvement. Bears point to execution risk in competitive oncology, no profitability in sight (EV/EBITDA is deeply negative), and a price-to-book of 89x that leaves little valuation cushion if data disappoints. Correlated peers EDIT and NKTX each gained over 13% on the week, suggesting the broader clinical-stage biotech tape is constructive — SMMT's 4.2% weekly gain trails that peer group move.
The October 20 earnings date is the next hard anchor — between now and then, any update on the ivonescimab OS interim analysis or HARMONi programme timelines will determine whether the Street's cautious upgrades harden into genuine conviction.
See the live data behind this article on ORTEX.
Open SMMT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
